BioNxt Solutions Inc. (CSE:BNXT)
Canada
· Delayed Price · Currency is CAD 0.650
+0.080 (14.04%)
Mar 9, 2026, 1:02 PM EST
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 11.26K CAD in the quarter ending September 30, 2025, a decrease of -34.17%. This brings the company's revenue in the last twelve months to 15.82K, down -62.34% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
15.82K
Revenue Growth
-62.34%
P/S Ratio
4,663.33
Revenue / Employee
n/a
Employees
n/a
Market Cap
73.78M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Planet 13 Holdings | 151.05M |
| Decibel Cannabis Company | 109.31M |
| Vext Science | 66.63M |
| Leef Brands | 45.21M |
| Medexus Pharmaceuticals | 136.34M |
| C21 Investments | 45.62M |
| LSL Pharma Group | 26.80M |
| Grown Rogue International | 30.85M |
BioNxt Solutions News
- 10 days ago - BioNxt Solutions Inc.: BioNxt Announces Closing of Shares for Debt Settlement - Finanz Nachrichten
- 10 days ago - BioNxt Announces Closing of Shares for Debt Settlement - Wallstreet:Online
- 20 days ago - BioNxt Solutions Inc.: BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis - Finanz Nachrichten
- 20 days ago - BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis - Wallstreet:Online
- 4 weeks ago - BioNxt Solutions Inc.: BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery - Finanz Nachrichten
- 4 weeks ago - BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery - Wallstreet:Online